Key facts
- It has raised $271.1M; the latest was Later Stage VC ($150.0M) in Jul 2024.
- Notable investors include Canaan Partners, Bayern Kapital, Forbion, European Investment Fund, Gilde Healthcare — 15 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for Catalym
- ·The full record, as it builds
Funding rounds
No funding rounds for Catalym are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Catalym
Operator of a biopharmaceutical company intended to transform cancer patients' lives by engaging their own immune systems. The company engages in developing antibodies that transform the tumor micro-environment and substantially improve treatment options by making tumors accessible and susceptible again to the patient's own immune system, enabling cancer patients to improve their survival and quality of life.
- Sector
- Healthcare
- HQ
- Planegg, Germany
- Founded
- 2016
- Employees
- 46
- Website
- catalym.com/
- Ownership
- Privately Held (backing)
Catalym doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Catalym shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Catalym in its N-PORT filings yet. We sweep new filings monthly.